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Abstract
Phototherapy consists in the use of ultraviolet (UV) radiation from artificial sources for
therapeutic purposes. Despite the introduction of new and powerful drugs (including
biological and target therapies), phototherapy remains an established, lower cost, and
effective option for the treatment of many common skin diseases.
In systemic photochemotherapy or PUVA, photosensitizing agents of the family of
Psoralens are used in combination with UVA, i.e. with long wave ultraviolet radiation .
Psoralens strongly enhance the effect of UVA alone, as they interact with biological
macromolecules, causing the production of oxygen free radicals within the photoacti‐
vated cells. However, systemic administration of psoralens can be problematic, causing
possible negative interactions with other drugs and the onset of serious side effects.
To counteract these limitations, it has been developed the bath‐PUVA therapy, which
consists in the topical administration of psoralens by bathing the whole body surface in
an alcoholic solution of 8‐methoxypsoralen (8‐MOP); immediately afterwards this pre‐
treatment, the patient is UVA‐irradiated. This technique has several advantages over
conventional PUVA, including the use of a reduced UVA dosage, thus resulting in
minimal skin damage with complete elimination of skin photosensitivity within three
hours after the treatment; furthermore, it virtually eliminates systemic side effects and
drug interference due to the very limited percutaneous absorption of psoralens. Bath‐
PUVA is indicated and effective in the treatment of many chronic inflammatory
dermatoses (including psoriasis, atopic and allergic dermatitis, lichen ruber planus,
chronic urticaria, and mastocitosis), autoimmune skin diseases (including vitiligo, and
alopecia aerata), and premalignant/malignant lymphoproliferative conditions (includ‐
ing actinic reticulosis, parapsoriasis, and early stages of mycosis fungoides). Chronic and
refractory pruritus and graft‐versus‐host diseases can also benefit from bath‐PUVA.
Another emerging PUVA technique is gel‐PUVA, which is based on the application of
a gel‐based formulation of 8‐MOP on affected skin areas , followed by UVA radiation.
The formulation of 8‐MOP‐containing gels is conceived to increase bioavailability, limit
its spread to adjacent skin and improve cosmetic aspects, while making negligible the
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systemic absorption of the psoralen. Ultraviolet A (UVA) irradiation is administered by
cabins or partial devices according to the extension of the body areas to be treated. Gel‐
PUVA has produced its best responses in morfea, palmo‐plantar psoriasis, contact
dermatitis and vitiligo.
The purpose of this chapter is to provide a detailed description of the various
phototherapy techniques and discuss their possible applications to the treatment of
specific acute and chronic skin diseases.
Keywords: phototherapy, dermatological diseases, bath‐PUVA, gel‐PUVA, psoralen
1. Introduction
Phototherapy consists  in  the  use  of  ultraviolet  (UV) radiation from artificial  sources  for
therapeutic purposes and remains an established, lower cost, and effective option for the
treatment of many common skin inflammatory and immune‐related diseases [1–5]. Table 1
displays the major dermatological diseases and skin conditions in which phototherapy has
been proven to  be  an effective  therapeutic  strategy.  In  the  systemic  photochemotherapy
(PUVA), UVA radiation occurs after the oral administration of photosensitizing agents of the
family of Psoralens.
Indications
Inflammatory dermatoses Atopic dermatitis
Actinic prurigo
Contact dermatitis
Hydroa vacciniforme
Lichen ruber planus
Physical and chronic urticaria
Pruritus
Psoriasis
Seasonal and polymorphic light eruption
Premalignant and malignant skin diseases Actinic reticulosis
Lymphomatoid papulomatosis
Mastocytosis
Mycosis fungoides (Stage 1A–IIB)
Patch or plaque parapsoriasis
Others Alopecia areata
Erytropoietic protoporphyria
Vitiligo
Table 1. Indication to UVA and PUVA therapy.
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2. Psoralens
Psoralen (also called psoralene) is the progenitor of a family of natural organic compounds
known as linear furanocoumarin, that is, derivatives of coumarin by the addition of a furan
ring. Its methoxylated derivatives are commonly used in phototherapy and comprise the 5‐
methoxypsoralen (5‐MOP) and the 8‐methoxypsoralen (8‐MOP). 5‐MOP (or 4‐methoxy‐
furo[3,2‐g]benzopyrane‐7‐one, Bergaptene) is generally extracted from bergamot and many
other citrus essential oils, including those from lemon, sweet orange, bitter orange, and
mandarin, whereas the 8‐MOP (or 9‐methoxyfuro[3,2‐g][1]benzopyran‐7‐one, ammoidin,
methoxsalen, and xanthotoxin) is extracted from Ammi majus, a plant of the Ammi Umbelli‐
ferae family [6]. The absorption spectrum of psoralens ranges between 320 and 360 nm, in
vitro; in vivo, due to the interaction with biological structures, the spectrum extends toward a
longer wavelength, around 400 nm. Using artificial sources with a conventional emission
spectrum (such as Philips TL/09 lamps), the peak of sensitivity for 8‐MOP is between 335 and
355 nm.
Photosensitization determined by psoralen occurs by means of two mechanisms [7, 8]:
i. Photoaddition reactions: In the dark, psoralens intercalate between base pairs of the
DNA double helix. Upon UVA excitation, intercalated psoralens get photoactivated;
as a result of this reaction, they form [2 + 2]‐cycloadducts, primarily with adjacent
thymine bases, involving either their furan or pyrone moiety; more precisely, the [2
+ 2]‐type photoconjugation occurs between the 3,4‐pyrone and/or 4',5'‐furan double
bond of the intercalated psoralen and the pyrimidine 5,6 double bond. The furan
adduct is then capable of absorbing another UVA photon, resulting in interstrand
cross‐links [9]. DNA interstrand cross‐links are among the most cytotoxic types of
DNA damage; their repair is extraordinarily difficult for the cell since it requires the
coordination of proteins from several pathways, including nucleotide excision repair,
base excision repair, mismatch repair, homologous recombination, translation
synthesis, and proteins involved in Fanconi anemia [10]. Monoadducts and cross‐
links inhibit DNA‐readout processes, thus leading to necrosis or apoptosis of the
photodamaged cells [11]. Psoralens are highly soluble in body fluids, and therefore
they can form photoadducts with a variety of other molecules besides DNA,
including RNAs, proteins, and polyunsaturated fatty acids; actually, most of the
administered 8‐MOP have been found to be conjugated to proteins rather than to
nucleic acids or lipids [12]. Psoralen photoadducts to those molecules result in
disruption and silencing of a variety of metabolic and signaling pathways, thus
exerting a broad range of phototoxicity.
ii. Photodynamic reactions: Photoactivation of psoralens in the presence of oxygen results
in the formation of reactive oxygen species (ROS), including singlet oxygen and
superoxide radical anions. Thus, psoralens activate both type 1 photodynamic
mechanisms (i.e., the production of superoxide, hydrogen peroxide, and hydroxyl
radical (HO•) by electron transfer) and type 2 mechanisms (i.e., the production of
singlet oxygen (1O2) by energy transfer) [13]. Reactive oxygen species are extremely
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unstable and react with other molecules, causing a variety of cell damages, including
lipid peroxidation, DNA breaks, and DNA‐protein cross‐links (PMID: 24721421). To
counteract oxidative damage/stress, cells rely on a number of antioxidative defense
systems, including natural radical scavengers (e.g., tocopherol and vitamin A) and
different enzymes (e.g., superoxide dismutase, glutathione peroxidase, and catalase).
Adducted DNA by psoralens is also implicated in melanogenesis: modified nucleotides, in
particular oligonucleotides composed by two thymidine residues, stimulate cells to express
tyrosinase, a known key enzyme in melanin production, with variable effects in patients with
vitiligo vulgaris [14–17]. The demonstrated ability of furocoumarines to bind proteins,
including those of the lens, can induce cataract in long‐term therapy. Finally, it has to be noticed
that PUVA has also the ability to induce apoptosis of Langerhans cells, activated T‐lympho‐
cytes, neutrophils, macrophages, NK cells, fibroblasts, endothelial cells, and mast cells, thus
exerting a beneficial effect for the most common dermatoses [18].
2.1. Dosage
Pharmacokinetic studies have shown that psoralens absorption is subject to individual
variations, in terms of both mean plasma concentration and timing for reaching the maximum
peak. In addition, in the same individual, plasma concentration varies during the day, although
the maximum peak represents a constant [19–21].
Recommended doses are the following:
i. 8‐MOP: 0.6 mg/kg (or 25 mg/m2, for subjects weighing less than 60 kg) 2 h before
exposure if in a micronized form or 1 h before if in liquid or gelatinous form. The
dosage should then be adjusted according to the response.
ii. 5‐MOP: 1.2 mg/kg, 3.5 h before the treatment.
8‐MOP administration results in a photosensitization which reaches its maximum, 2–4 h after
the intake and disappears in 6–8 h. Psoralens are transported in the blood by serum proteins
(mainly albumin), and are predominantly catabolized in the liver by cytochrome P450
(CYP450)‐triggered oxidation. CYP450s make a large superfamily of heme‐containing
monooxygenases, which take care of the detoxification of many drugs [22]. Recent studies
have shown that CYP3A11 is the major target cytochrome for psoralens metabolism in mice
[23]. Another key cytochrome for detoxification or activation of many toxicologically
important substrates is CYP2B1 [24]. Psoralens are oxidized by CYP3A11 at the furan ring
to form a furan epoxide that binds to CYP 2B1 with a high stoichiometry [25]; after biding,
CYP 2B1 produces dihydrodiols, which are the final catabolic products of linear fucocou‐
marins [25]. In addition, 8‐MOP up‐regulates CYP1A1 expression, and can be a substrate for
this CYP450 [26]. CYP450s are encoded by highly polymorphic genes [27] and their expres‐
sion varies among individuals, in relation with alcohol intake and drug use; both these facts
provide an easy explanation for individual variations in response to psoralen‐related
therapies. About 75% of furanocoumarins catabolic products produced by the liver are
excreted in the urine as inactive hydroxylated‐ or glucurono‐conjugates derivatives within
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12 h; key proteins for this excretory function are the solute carrier (SLC) 22A family organic
cation/carnitine transporters (OCTs/OCTNs) and the organic anion transporters (OATs).
More specifically, the administration of furocoumarins up‐regulates renal OCT1, OCT2,
OCTN2, and OAT3 protein levels, as a result of increased gene expression in mice; in
addition, oxidized linear furocoumarins induce high expression of mURAT1, mMRP4, and
mGLUT9, which may also play important roles in renal transportation, and accumulation of
psoralen metabolites as well as in related kidney injury. Notably, 8‐MOP clearance in the lens
is rather slow, it being detectable in this organ for 18 h after oral intake [28].
2.2. Cautions
In view of the prolonged photosensitivity induced by 8‐MOP [29], it is mandatory to avoid
exposition to the sunlight after the treatment; to this purpose, eyes and lips should be protected
with glasses and sunscreen.
During treatment with psoralens, regular evaluation of liver function is needed and drug
should be reduced or discontinued if there is any sign of liver damage. The most frequent
pharmacological interactions are with other topical or systemic photoactive drugs (e.g.,
phenothiazine, chlorothiazide and derivatives, sulfonylureas, sulfonamides, neomycin, and
bergamot essence). Diet with low (or free) coumarins should also be recommended, which are
mainly contained in fig, cedar, lime, parsley, mustard, carrots and celery, and parsnips.
The most frequently observed side effects related to 8‐MOP administration include severe
burns, gastric distress, nausea, nervousness, insomnia, and depression.
Major contraindications to PUVA therapy are summarized in Table 2.
Contraindications
Absolute Major Relative
Autoimmune diseases Age >10 years Age >16 years
Basal cell carcinoma syndrome Actinic keratosis Bullous skin diseases
Dysplastic nevus syndrome Personal history of nonmelanoma skin
cancer
Cataract
Personal history of melanoma Previous exposure to UVA >1500 J/cm2 Photosensitization
Porphyry Previous exposure to X‐ray or arsenic Photo type I
Pregnancy and lactation Systemic immunosuppressive therapy Poor compliance
Severe heart failure Renal and/or hepatic failure
Systemic lupus erythematosus;
Dermatomyositis
Xeroderma pigmentosum and other congenital
defects of DNA repair mechanisms
*Photo type I is characterized by pale white skin, blue or hazel eyes, and blond or red hair; patients with photo‐type I
always have burns, does not tan.
Table 2. Contraindications to PUVA therapy.
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3. UV irradiation
The most frequently used lamps for phototherapy are fluorescent, low‐pressure mercury vapor
tubes (e.g., Philips TL/09, Philips CLEO‐UVA or Sylvania F 85 tubes) with an emission
spectrum ranging from 320 to 450 nm, and an emission peak at 352 nm. PUVA units are either
whole‐body cabins or small‐panel irradiators for the treatments of hands and feet or other
restricted areas of the body. To provide consistency and repeatability of treatment doses, it is
fundamental to measure the emission by calibrated radiometers‐photometers, sensitive to the
spectrum emitted by the lamps. Treatment times are automatically calculated on the basis of
variables such as (i) total or daily usage time of the lamps, (ii) environmental and patient’s
conditions (temperature, humidity, dust, and distribution of adipose tissue), and (iii) presence
of other UV sources. When devices devoid of dosimeters are used, the dosage should be
calculated according to the formula: Dose (mJ/cm2) = irradiance (mW/cm2) × time (seconds);
special tables are then used to calculate the appropriate dosage, according to patient’s photo‐
type. In any case, it is recommended a semiannual or annual assessment of the UVA cabin or
panel with external radiometer‐photometer calibrated to the National Physics Laboratory,
which will provide an adjustment for timing and doses [5, 6].
3.1. Dose assessment
Dose assessment, according to the different published protocols, is based on (i) evaluation of
the Fitzpatrick phototype, (ii) calculation of the minimal phototoxic dose (MPD), that is, the
lowest UVA dose that produces a perceptible erythema after psoralen administration, and (iii)
assessment of an attack dosage equal to 50% of MPD.
The sessions are initially carried out three to four times a week and then reduced to two times
a week after a clinical improvement has been obtained. The possibility of performing one
session every 7–10 days as maintenance therapy can be considered. Side effects are resumed
as shown in Table 3.
Side effects
Early Late
Gastric intolerance Anti‐DNA and antinucleus antibodies (low title)
Hypertrichosis or alopecia Carcinogenesis (actinic keratosis, NMSCs, melanomas)
Neomelanogenesis and stratum corneum thickening Cataract
Pain Disorder of pigmentation
Photo‐inducted dermatitis Idiopathic guttate hypomelanosis
Phototoxic exanthema Melanocytes dystrophies
Skin dryness and pruritus
Teratogenicity
Table 3. Side effects related to PUVA therapy.
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4. Topical photochemotherapy: bath-PUVA
Bath‐PUVA therapy consists in the immersion of the whole body in a bath containing an 8‐
MOP alcoholic solution, at concentrations ranging from 1 to 3 mg/L, for a time varying from
15' to 20'. Then, the patient is exposed to increasing doses of UVA, which varies in relation to
the phototype, with a minimal initial doses of 0.25–0.50 J/cm2 and progressive increments of
0.25 J/cm2 up to a maximum of 5–7 J/cm2 .
Figure 1. Plaque psoriasis before (A, C, E, G) and after (B, D, F, H) bath‐PUVA therapy.
Figure 2. Ichthyosis‐like atopic dermatitis before (A and C) and after (B and D) bath‐PUVA therapy.
This modality of treatment minimizes short‐ and long‐term side effects due to the systemic
administration of the drug [19, 30–33]. Three hours after treatment, photosensitivity is negligible,
due to the low systemic absorption of 8‐MOP; thus, patients can avoid the use of photoprotec‐
tions, including sunglasses [34, 35]. Gas chromatography and mass spectrometry analyses have
shown that plasmatic trixolaren concentrations range between 0.27 and 12.5 ng/ml after the
ingestion of a 0.6 mg/kg dose and between 9 ng/ml and 25 pg/ml after bath‐PUVA [20, 36].
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Figure 3. Stage I mycosis fungoides before (A) and after (B) bath‐PUVA therapy.
Figure 4. Palmoplantar psoriasis before (A and C) and after (B and D) gel‐PUVA therapy; eczematized psoriasis before
(E and G) and after (F and H) gel‐PUVA therapy.
In the skin, the drug absorption peak occurs within 15–35 min; the maximum concentration is
reached in the stratum corneum and the removal of this cell layer (by “stripping”) significantly
enhances the possibility of drug penetration to the underlying layers. The higher psoralen
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concentration in superficial layers of the epidermis justifies the increased effectiveness of this
type of treatment in those diseases in which the epidermal involvement is massive [30, 36,
37]. The concentration measured by microanalytical techniques is instead of 1.7–6.6 ng/ml after
oral intake and of 200–520 ng/ml after the bath.
Literature reports encourage results obtained with bath‐PUVA in the treatment of several
inflammatory [38–47] and lymphoproliferative skin diseases [48–52]. Figures 1–4 report same
examples of results obtained with bath‐PUVA at our center.
4.1. Treatment
Before treatment, an accurate collection of clinical data is mandatory; patient should be
informed about the treatment modality, its potential benefits and risks, and the need to avoid
other potentially photosensitizing agents. Skin should be carefully examined and nevi should
be covered with high‐protection sunscreen, as well as the lips and genital areas; patient should
also wear sunglasses during treatment and up to 3 h afterwards. At the end of treatment, we
recommended also a shower, to remove residual traces of the drug from the skin, and the
application of topical emollients [53, 54]. The treatment requires special attention and the
protocol described above must necessarily be adapted to each patient, on the basis of the
phototype and other clinical characteristics.
5. Topical photochemotherapy: gel-PUVA therapy
The gel‐PUVA therapy is a variant of the cream‐PUVA therapy and consists in the application
of a 0.05% of 8‐MOP gel on restricted skin areas, 20–30 min before the irradiation. The
preparation of the 8‐MOP gel is galenical; the psoralen is dissolved, in order to obtain a higher
bioavailability and better cosmetic aspects and to avoid the “border effect.” The UVA radiation
could be realized through cabin or panels according to the extent of the body areas affected by
the disease, with an irradiation spectrum of 320–370 nm. Dose calculation is performed
manually, because panels are not equipped with dosimeter; hence, every 6 months, their
calibration is mandatory. Usually, an initial dose of 0.25–0.50 J/cm2 is used, with a progressive
increase in 0.25–0.50J/cm2 for each session, up to a maximal dose of 9 J/cm2. Treatment sessions
are performed three times/week for the first month of treatment and then reduced to two times/
week in the second month and to one time/week in the third month. A weekly maintenance
session could also be proposed.
Best responses to gel‐PUVA treatment are described for morphea, palmoplantar psoriasis,
contact dermatitis, and vitiligo [43, 55–57]. Inclusion and exclusion criteria are those described
for systemic PUVA.
The amount of 8‐MOP that is absorbed with this method is negligible [21, 58] and the only side
effects that have been described are transitory erythema and pruritus, which can be easily
managed with topical moisturizing creams. In a few cases, peripheral hyperpigmentation of
the treated areas has also been reported [59].
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In literature, also a topical psoralen‐narrow‐band UVB therapy has been described, based on
the association of topical 8‐MOP and narrow‐band UVB irradiation [60–62].
6. Conclusions
Phototherapy and especially topic phototherapy are efficient treatment methods for a variety
of dermatological diseases, able to induce complete and durable responses in several inflam‐
matory, immune‐mediated, and neoplastic skin diseases. Relapses are rare, due to the absence
of tachyphylaxis. Although the cost of phototherapy is low, the relative discomfort and the
time required to reach the site of the treatment should be considered.
For the risk of carcinogenesis, a number of factors should be taken into account, including
dose, age at the treatment, other potentially carcinogenic drugs, photodamaged skin areas,
and the type of treatment (a lower carcinogenetic potential has been reported for bath‐PUVA
in respect to systemic PUVA). The analysis of 11 clinical trials, 10 of which were conducted on
psoriatic patients (for a total of about 3400 patients), did not show an increased risk of
melanoma [63–66] or of nonmelanoma skin cancer after UVA phototherapy [60, 66, 67].
However, another study [63, 66] conducted on patients previously treated with PUVA therapy
and subsequently exposed to a high amount of UVB (for more than 300 treatments) demon‐
strated a small but significant increased risk of both squamous (relative risk (RR): 1.37) and
basal cell carcinomas (RR: 1.45). The risk was further increased for patients who received less
than 100 PUVA but more than 300 UVB treatments (RR: 2.75 for SCC and 3.00 per BCC). An
increased risk to develop malignant melanoma has also been reported, based on the phototype
and on the number of treatments; melanoma could arise more than 20 years after the start of
therapy, showing a greater aggressiveness than in the general population. An increased risk
to develop other cancers (colon, lung, pancreas, and kidney) has not been documented. The
putative carcinogenetic risk of narrow‐band UVB is higher than for UVA, but its increased
effectiveness requires lower cumulative doses, resulting in a reduced actual risk [60].
In summary, an accurate follow‐up of patients is essential, in order to detect precancerous skin
lesions, and identify suspicious melanocytic lesions, which must be excised. Accurate calcu‐
lation of cumulative doses, number of treatments and their cumulative dosage, represents an
absolute requirement for a correct planning of phototherapy. In addition, alternating PUVA
therapy with other topical or systemic treatments can significantly reduce the carcinogenic
potential of phototherapy.
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